Nurix Therapeutics announces FDA ODD granted to bexobrutideg
Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to bexobrutideg, ...
Nurix Gets FDA Orphan Designation for Bexobrutideg in Waldenstrom Macroglobulinemia
Nurix on Monday said the FDA granted orphan-drug designation to bexobrutideg, also known as NX-5948, for the treatment of Waldenstrom macroglobulinemia, a slow growing type of non-Hodgkin's lymphoma ...
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström MacroglobulinemiaFirst-in-class ...